Assembly Biosciences (NASDAQ:ASMB) Shares Pass Above Two Hundred Day Moving Average – What’s Next?

Shares of Assembly Biosciences, Inc. (NASDAQ:ASMB) crossed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $15.65 and traded as high as $17.68. Assembly Biosciences shares last traded at $17.37, with a volume of 23,726 shares.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the company. Jefferies Financial Group raised Assembly Biosciences from a “hold” rating to a “buy” rating and raised their target price for the company from $2.00 to $35.00 in a report on Friday, September 20th. HC Wainwright reiterated a “neutral” rating on shares of Assembly Biosciences in a research note on Friday, December 27th.

Assembly Biosciences Stock Up 0.1 %

The business has a fifty day moving average of $16.03 and a two-hundred day moving average of $15.65.

Insider Buying and Selling at Assembly Biosciences

In related news, Director Michael Houghton purchased 3,202 shares of the company’s stock in a transaction on Monday, December 30th. The stock was bought at an average price of $15.61 per share, with a total value of $49,983.22. Following the completion of the transaction, the director now owns 3,202 shares of the company’s stock, valued at approximately $49,983.22. This represents a ? increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 5.10% of the stock is owned by corporate insiders.

Institutional Trading of Assembly Biosciences

Large investors have recently made changes to their positions in the stock. JPMorgan Chase & Co. raised its stake in Assembly Biosciences by 5,137.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 3,509 shares of the biopharmaceutical company’s stock valued at $53,000 after purchasing an additional 3,442 shares during the last quarter. Acadian Asset Management LLC grew its holdings in shares of Assembly Biosciences by 131.0% during the second quarter. Acadian Asset Management LLC now owns 13,558 shares of the biopharmaceutical company’s stock worth $184,000 after buying an additional 7,690 shares in the last quarter. FMR LLC raised its position in shares of Assembly Biosciences by 29.7% in the third quarter. FMR LLC now owns 15,855 shares of the biopharmaceutical company’s stock valued at $240,000 after buying an additional 3,635 shares during the last quarter. Renaissance Technologies LLC lifted its stake in shares of Assembly Biosciences by 39.2% during the second quarter. Renaissance Technologies LLC now owns 54,911 shares of the biopharmaceutical company’s stock valued at $753,000 after buying an additional 15,451 shares during the period. Finally, Armistice Capital LLC acquired a new stake in Assembly Biosciences during the second quarter worth approximately $6,421,000. Institutional investors and hedge funds own 19.92% of the company’s stock.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.